Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Bladder Cancer

AGS15E for Metastatic Urothelial Cancer
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Status Conditions Phase Study ID
Recruiting Metastatic Urothelial Cancer Phase I NCT01963052
Summary

The objectives of this study are to assess the safety, pharmacokinetics, immunogenicity and anti-tumor activity of AGS15E in subjects with metastatic urothelial cancer who failed at least one prior chemotherapy regimen for metastatic disease.


Investigator
Evan Ya-Wen Yu, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Histologically confirmed Transitional Cell Carcinoma of the Urothelium (TCCU) (i.e., cancer of the bladder, renal pelvis, ureter, or urethra).
  • Must have failed at least one prior chemotherapy regimen for metastatic disease and/or is unfit for cisplatin-based chemotherapy
  • Subjects must have measureable disease according to RECIST (version 1.1)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Life expectancy of ≥ 3 months
  • Adequate hematologic function
  • Adequate renal function
  • Adequate liver function
  • Gamma GT ≤ 1.5 x ULN (upper limit of normal)
  • Lipase within the normal range
  • Amylase ≤ 1.5 x ULN
Exclusions (conditions that would prevent participation in this study)
  • Preexisting sensory neuropathy Grade ≥ 2 or motor neuropathy Grade ≥ 2
  • Uncontrolled central nervous system metastases
  • Use of any investigational drug within 14 days or 5 half-lives prior to the first dose of study drug Any anticancer therapy, including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy or any other agents to treat cancer within 14 days prior to the first dose of study drug
  • Any P-gp inducers/inhibitors or strong CYP3A inhibitors within 14 days prior to the first dose of study drug
  • History of thromboembolic events and/or bleeding disorders ≤ 3 months (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) prior to the first dose of study drug
  • Positive Hepatitis B surface antigen test
  • Positive Hepatitis C antibody test
  • Decompensated liver disease as evidenced by clinically significant ascites refractory to diuretic therapy, hepatic encephalopathy, or coagulopathy
  • History of a primary invasive malignancy not listed in the inclusion criteria, which has not been in remission for at least 3 years. The following are exempt from the 3 year limit:
    • Non-melanoma skin cancer;
    • adenocarcinoma of the prostate that has been surgically treated with a post-treatment PSA that is undetectable;
    • cervical carcinoma in situ on biopsy or squamous intraepithelial lesion on Pap smear; and
    • definitively treated, stage I/II ER+ breast cancer
  • Active infection requiring treatment ≤7 days before first dose of study drug
  • History of eye surgery within 6 months, presence of cataracts or other ocular disorders significantly affecting vision
  • Condition or situation which, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with subject's participation in the study
Last Updated
March 28, 2014
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.